SEC Form 4 · accession 0001179110-15-005915
KYTHERA BIOPHARMACEUTICALS INC · KYTH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Keith R Leonard
Officer — President & CEO · Director
Period of report
Apr 1, 2015
Accepted (ET)
Apr 2, 2015 · 8:34 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001436304
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF7,F2 | Apr 1, 2015 | S | 13,148 | $48.108 | D | 861,090 | I | See footnote |
| Common StockF8,F2 | Apr 1, 2015 | S | 400 | $49.148 | D | 860,690 | I | See footnote |
| Common StockF3 | holding | — | — | — | 49,649 | I | See footnote | |
| Common StockF4 | holding | — | — | — | 49,649 | I | See footnote | |
| Common StockF5 | holding | — | — | — | 189 | I | See footnote | |
| Common StockF6 | holding | — | — | — | 189 | I | See footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan which expires April 30, 2015.
- F2Shares held by Leonard Family Trust, dated August 28, 1996, Keith Richard Leonard, Jr. and Nanette LaRosa Leonard, Trustees.
- F3Shares held by Keith Richard Leonard, Jr., Retained Annuity Trust, Dated 12 April, 2010, Keith Richard Leonard, Jr., Trustee.
- F4Shares held by Nanette LaRosa Leonard, Retained Annuity Trust, Dated 12 April, 2010, Keith Richard Leonard, Jr., Trustee.
- F5Shares held by Keith R. Leonard III. Keith R. Leonard III is the son of the Reporting Person.
- F6Shares held by Nina R. Leonard. Nina R. Leonard is the daughter of the Reporting Person.
- F7The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $47.88 to $48.77, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F8The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $48.81 to $49.51, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.